All In Biotech

Drug Trial Radar · NCT03651128

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 386 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

386

Actual

Start

Apr 16, 2019

Primary completion

Apr 13, 2026

Study completion Apr 13, 2026

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.

Conditions

  • Multiple Myeloma

Interventions

  • bb2121Biological

    bb2121

  • DaratumumabDrug

    Daratumumab

  • PomalidomideDrug

    Pomalidomide

  • DexamethasoneDrug

    Dexamethasone

  • BortezomibDrug

    Bortezomib

  • IxazomibDrug

    Ixazomib

  • LenalidomideDrug

    Lenalidomide

  • CarfilzomibDrug

    Carfilzomib

  • ElotuzumabDrug

    Elotuzumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Minimum of 5 years from randomization

Locations

62 sites in 13 countries. Site status is shown where the registry gives one.

  • Local Institution - 109

    Birmingham, Alabama

  • Local Institution - 141

    Scottsdale, Arizona

  • Local Institution - 145

    Los Angeles, California

  • Local Institution - 122

    Los Angeles, California

  • Local Institution - 124

    Palo Alto, California

  • Local Institution - 142

    Aurora, Colorado

  • Local Institution - 108

    Jacksonville, Florida

  • Local Institution - 102

    Tampa, Florida

  • Local Institution - 131

    Atlanta, Georgia

  • Local Institution - 140

    Atlanta, Georgia

  • Local Institution - 139

    Chicago, Illinois

  • Local Institution - 100

    Indianapolis, Indiana

  • Local Institution - 112

    Westwood, Kansas

  • Local Institution - 104

    Baltimore, Maryland

  • Local Institution - 134

    Boston, Massachusetts

  • Local Institution - 123

    Boston, Massachusetts

  • Local Institution - 120

    Ann Arbor, Michigan

  • Local Institution - 125

    Rochester, Minnesota

  • Local Institution - 114

    St Louis, Missouri

  • University Of Nebraska

    Omaha, Nebraska

  • Local Institution - 138

    Hackensack, New Jersey

  • Local Institution - 119

    New York, New York

  • Local Institution - 115

    New York, New York

  • Local Institution - 135

    New York, New York

  • Local Institution - 113

    Durham, North Carolina

  • Local Institution - 111

    Philadelphia, Pennsylvania

  • Local Institution - 110

    Philadelphia, Pennsylvania

  • Local Institution - 101

    Pittsburgh, Pennsylvania

  • Local Institution - 106

    Nashville, Tennessee

  • Local Institution - 118

    Dallas, Texas

  • Local Institution - 103

    Dallas, Texas

  • Local Institution - 132

    Houston, Texas

  • Local Institution - 136

    Salt Lake City, Utah

  • Local Institution - 105

    Seattle, Washington

  • Local Institution - 107

    Madison, Wisconsin

  • Froedtert Hospital BMT Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Local Institution - 202

    Leuven, Belgium

  • Local Institution - 302

    Calgary, Alberta, Canada

  • Local Institution - 303

    Toronto, Ontario, Canada

  • Local Institution - 402

    Lille, France

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.